Davies A, et al. - Among participants recruited from 107 cancer centers in the UK (n=94) and Switzerland (n=13) in REMoDL-B (randomized evaluation of molecular guided therapy for diffuse large B-cell lymphoma with bortezomib), researchers used gene-expression profiling to determine if adding bortezomib to standard therapy could improve outcomes in patients with biologically distinct subtypes of diffuse large B-cell lymphoma (germinal center and activated B cell). Findings revealed no improvement in progression-free survival following the addition of bortezomib to standard therapy. For prospective stratification, randomization, and successive analysis of biologically different subgroups of patients with diffuse large B-cell lymphoma, real-time molecular characterization was used for the first time in a large-scale study.